Wolverine Trading’s Inovio Pharmaceuticals INO Stock Holding History

Wolverine Trading’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-21,200	Closed	-$124K	–	5548
2024 Q3	$124K	Sell	21,200 -12,100	-36%	-$99.8K	﹤0.01%	4287
2024 Q2	$269K	Buy	+33,300	New	+$350K	﹤0.01%	3521
2023 Q1	–	Sell	-2,783	Closed	-$52K	–	4567
2022 Q4	$52K	Sell	2,783 -2,784	-50%	-$63.1K	﹤0.01%	3570
2022 Q3	$112K	Buy	5,567 +1,550	+39%	+$39.7K	﹤0.01%	3868
2022 Q2	$86K	Sell	4,017 -1,508	-27%	-$42.5K	﹤0.01%	3890
2022 Q1	$242K	Sell	5,525 -1,975	-26%	-$89K	﹤0.01%	4169
2021 Q4	$467K	Buy	+7,500	New	+$601K	﹤0.01%	3547
2021 Q3	–	Sell	-11,833	Closed	-$1.34M	–	6571
2021 Q2	$1.34M	Sell	11,833 -59	-0.5%	-$5.67K	﹤0.01%	2446
2021 Q1	$1.26M	Sell	11,892 -5,900	-33%	-$776K	﹤0.01%	2464
2020 Q4	$1.92M	Buy	+17,792	New	+$2.37M	﹤0.01%	1757
2020 Q3	–	Sell	-12,225	Closed	-$4.65M	–	4834
2020 Q2	$4.65M	Buy	+12,225	New	+$1.96M	0.01%	851

Other funds holding INO

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wolverine Trading's INO Position: Q4 2024 in Review

Wolverine Trading sold out of Inovio Pharmaceuticals (INO) in Q4 2024, closing a stake of 12,161 shares — an estimated $53.8K sold.

Wolverine Trading first reported a position in INO in Q2 2020 and held it in 8 quarters. The position peaked at $469K in Q2 2020. 104 funds tracked by Wall St. Rank hold INO as of Q4 2024.

Wolverine Trading reported no remaining Inovio Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Wolverine Trading sold 12,161 Inovio Pharmaceuticals shares in Q4 2024, an estimated $53.8K.
Wolverine Trading first reported a position in Inovio Pharmaceuticals in Q2 2020 and held it in 8 quarters.
Wolverine Trading's Inovio Pharmaceuticals position peaked at $469K in Q2 2020.
104 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2024.

Based on Wolverine Trading's 13F filing for Q4 2024, filed 14 Feb 2025.